Pathological Findings and Magnetic Resonance Imaging Concordance at Salvage Radical Prostatectomy for Local Recurrence following Partial Ablation Using High Intensity Focused Ultrasound.


Journal

The Journal of urology
ISSN: 1527-3792
Titre abrégé: J Urol
Pays: United States
ID NLM: 0376374

Informations de publication

Date de publication:
06 2019
Historique:
pubmed: 8 2 2019
medline: 9 8 2019
entrez: 8 2 2019
Statut: ppublish

Résumé

We describe the pathological characteristics of recurrence following high intensity focused ultrasound partial ablation in men treated with salvage robot-assisted radical prostatectomy. We assessed the sensitivity of magnetic resonance imaging before salvage robot-assisted radical prostatectomy in these men. A total of 35 men underwent salvage robot-assisted radical prostatectomy after high intensity focused ultrasound partial ablation from 2012 to 2018. We compared clinicopathological characteristics before ultrasound and before salvage prostatectomy after ultrasound to histopathology on salvage prostatectomy. We assessed infield recurrence, out of field disease, positive surgical margins and magnetic resonance imaging sensitivity before salvage robot-assisted radical prostatectomy. Before high intensity focused ultrasound 55.9% of men had multifocal disease and 47.1% had Gleason 3 + 3 disease outside the treatment field. Median time to salvage prostatectomy was 16 months (IQR 11-26). Indications for salvage prostatectomy were infield recurrence in 55.8% of cases, out of field recurrence in 20.6%, and infield and out of field recurrence in 23.5%. On salvage prostatectomy histopathology revealed significant cancer, defined as ISUP (International Society of Urological Pathology) 2 or greater, infield in 97.1% of cases, out of field in 81.3%, and infield and out of field in 79.4%. Of the cases 82.4% were adversely reclassified at salvage prostatectomy compared to 67.6% before ultrasound. The positive surgical margin rate was 40.0%. Of the positive margins 84.6% were in the region of previous ultrasound despite wide excision, including pT2 in 28.6%, pT3 in 47.6% and size 3 mm or greater, pT3 or multifocal (ie significant) in 31.4%. After ultrasound the sensitivity of magnetic resonance imaging for infield and out of field recurrence was 81.8% and 60.7%, respectively. Salvage robot-assisted radical prostatectomy may confer a higher risk of positive surgical margins, upgrading and up-staging than primary robot-assisted radical prostatectomy. High intensity focused ultrasound carries a risk of recurrence inside and outside the ablation zone. This information may inform salvage surgical planning and patient counseling regarding the choice of initial therapy and salvage treatment after high intensity focused ultrasound.

Identifiants

pubmed: 30730409
doi: 10.1097/JU.0000000000000135
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1134-1143

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Auteurs

James Edward Thompson (JE)

Department of Uro-Oncology, University College London Hospital , Oxford , United Kingdom.

Ashwin N Sridhar (AN)

Department of Uro-Oncology, University College London Hospital , Oxford , United Kingdom.
Division of Surgery and Interventional Sciences, University College London , Oxford , United Kingdom.

Wei Shen Tan (WS)

Department of Uro-Oncology, University College London Hospital , Oxford , United Kingdom.
Division of Surgery and Interventional Sciences, University College London , Oxford , United Kingdom.

Alex Freeman (A)

Department of Uro-Pathology, University College London Hospital , Oxford , United Kingdom.

Aiman Haider (A)

Department of Uro-Pathology, University College London Hospital , Oxford , United Kingdom.

Clare Allen (C)

Department of Uro-Radiology, University College London Hospital , Oxford , United Kingdom.

Caroline M Moore (CM)

Department of Uro-Oncology, University College London Hospital , Oxford , United Kingdom.

Clement Orczyk (C)

Department of Uro-Oncology, University College London Hospital , Oxford , United Kingdom.
Division of Surgery and Interventional Sciences, University College London , Oxford , United Kingdom.

Giorgio Mazzon (G)

Department of Uro-Oncology, University College London Hospital , Oxford , United Kingdom.

Pramit Khetrapal (P)

Department of Uro-Oncology, University College London Hospital , Oxford , United Kingdom.
Division of Surgery and Interventional Sciences, University College London , Oxford , United Kingdom.

Greg Shaw (G)

Department of Uro-Oncology, University College London Hospital , Oxford , United Kingdom.
Division of Surgery and Interventional Sciences, University College London , Oxford , United Kingdom.

Prabhakar Rajan (P)

Department of Uro-Oncology, University College London Hospital , Oxford , United Kingdom.
Center of Molecular Oncology, Barts Cancer Institute, Queen Mary University of London , Oxford , United Kingdom.

Anna Mohammed (A)

Department of Uro-Oncology, University College London Hospital , Oxford , United Kingdom.

Timothy P Briggs (TP)

Department of Uro-Oncology, University College London Hospital , Oxford , United Kingdom.

Senthil Nathan (S)

Department of Uro-Oncology, University College London Hospital , Oxford , United Kingdom.
Division of Surgery and Interventional Sciences, University College London , Oxford , United Kingdom.

John D Kelly (JD)

Department of Uro-Oncology, University College London Hospital , Oxford , United Kingdom.
Division of Surgery and Interventional Sciences, University College London , Oxford , United Kingdom.

Prasanna Sooriakumaran (P)

Department of Uro-Oncology, University College London Hospital , Oxford , United Kingdom.
Division of Surgery and Interventional Sciences, University College London , Oxford , United Kingdom.
London and Nuffield Department of Surgical Sciences, University of Oxford , Oxford , United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH